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ABSTRACT 
 
Cigarette smoke has significant toxic effects on the immune system, and increases the risk of 
developing autoimmune diseases; one immunosuppressive effect of cigarette smoke is that it 
inhibits the T cell-stimulating, immunogenic properties of myeloid dendritic cells (DCs).  As 
the functions of DCs are regulated by intra-cellular signaling pathways, we investigated the 
effects of cigarette smoke extract (CSE) and nicotine on multiple signaling molecules and 
other regulatory proteins in human DCs to elucidate the molecular basis of the inhibition of 
DC maturation and function by CSE and nicotine.  Maturation of monocyte-derived DCs was 
induced with the TLR3-agonist poly I:C or with the TLR4-agonist lipopolysaccharide, in the 
absence or presence of CSE or nicotine.  Reverse-phase protein microarray was used to 
quantify multiple signaling molecules and other proteins in cell lysates.  Particularly in poly 
I:C-matured DCs, cigarette smoke constituents and nicotine suppressed the expression of 
signaling molecules associated with DC maturation and T cell stimulation, cell survival and 
cell migration.  In conclusion, constituents of tobacco smoke suppress the immunogenic 
potential of DCs at the signaling pathway level.   
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1. Introduction 
Myeloid dendritic cells (mDCs) are pivotal in maintenance of self-tolerance and 
induction of autoimmunity [1, 2].  Activated mDCs upregulate MHC molecules and co-
stimulatory proteins like CD80/CD86, and stimulate activation of naïve T cells [3, 4].  
Immature, ‘steady state’, mDCs express little CD80/86 and induce Th/Tc anergy and Treg 
activation [1, 5].  
The phenotype and functions of mDCs are affected by tobacco smoke, with 
suppression of T cell-stimulating, immunogenic properties of mDCs by CS constituents [6].  
Evidence for this derives from human and murine in vivo and in vitro studies.  In a mouse 
smoking model, DCs show low expression of co-stimulatory molecules and reduced 
stimulation T cells [7, 8].  Similarly, in humans, smoking impairs the maturation of mDCs in 
the lungs, evidenced by reduced expression of CD40, CD83 and CCR7 [9, 10].  Treatment of 
mouse bone marrow-derived DCs (bmDCs) with cigarette smoke extract (CSE) differentially 
affects T cell stimulation, depending on T cell phenotype (CD4+ or CD8+) [11] and length of 
treatment (chronic exposure to CSE suppresses DC maturation) [12].  The maturation of 
human monocyte-derived DCs (moDCs), and their ability to stimulate Th1 and Th17 cells, is 
also suppressed by CSE [13-15].  Although numerous chemicals within CS affect immune 
cells [6], nicotine is the main addictive component and has well-documented suppressive 
effects on IL-12 production and Th1 stimulation by human moDCs and mouse bmDCs, 
promoting instead Th2 responses [16-19]. Immunosuppressive effects of nicotine are exerted 
particularly via the a7 nicotinic acetylcholine receptor [20]. 
The differentiation, regulation and functions of DCs, as with all cells, is dependent on 
intra-cellular signaling pathways.  The aim of the present study was to investigate the effects 
of CSE and nicotine on signaling pathways in human moDCs as this would enhance 
understanding the effects of tobacco constituents on DCs, and the association between 
smoking and autoimmunity.  This was achieved by reverse-phase protein microarray (RPPA) 
to quantify multiple signaling molecules in small volumes of cell lysates using highly specific 
antibodies.  We previously used RPPA to demonstrate constitutive activation of multiple pro-
inflammatory signaling pathways in an autoinflammatory disease [21].  Here, we demonstrate 
down-regulation of signaling pathways and other proteins in moDCs by CSE and nicotine 
that is consistent with inhibition of DC maturation, survival and migration. 
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2 Materials and methods 
2.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
Blood samples were collected from healthy volunteers with informed consent (University of 
Nottingham Medical School Ethics Committee; BT 15/03/2010). Buffy coats and leucocytes 
cones from anonymized healthy donors were from the Regional Blood Transfusion Service 
(Sheffield, UK). PBMCs were separated by density gradient centrifugation using Histopaque-
1077 (Sigma-Aldrich). The cells were washed and resuspended in RPMI complete medium, 
i.e. RPMI-1640 medium (Sigma-Aldrich) supplemented with 10mM HEPES, 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 2mM L-glutamine (Sigma-Aldrich) and 10% fetal bovine 
serum (FBS). 
 
2.2 Isolation of CD14+ monocytes 
CD14+ monocytes were isolated from PBMCs using CD14+ microbeads (Miltenyi Biotec, 
Surrey, UK) by positive selection (manufacturer’s protocol). The separated cells were 
resuspended in RPMI complete medium and their purity was checked by flow cytometry 
(Beckman-Coulter FC500) following staining with anti-CD14-FITC (Beckman-Coulter).  
Fresh blood, buffy coats and leucocyte cones yielded CD14+ monocytes with 84%-93% 
purity. 
 
2.3 Generation and phenotyping of immature and mature moDCs 
To generate immature moDCs, CD14+ cells were cultured at 5x105 cells/ml in RPMI complete 
medium supplemented with 50ng/ml GM-CSF and 20ng/ml IL-4 (R&D Systems) at 37°C, 
5% CO2 for five days; 500µl of fresh medium and cytokines were added on day three.  To 
generate mature moDCs, day five immature moDCs were stimulated with 100ng/ml LPS 
(Sigma-Aldrich, Cat. No. L4391) or 30µg/ml poly I:C (InvivoGen) and incubated at 37°C, 
5% CO2 for 24h. Staining for flow cytometry was performed essentially as described 
previously [22]; details are given in Supplementary table 1.   
Detection of cytokines secreted by immature and mature dendritic cells was 
performed by protein micro-array, as previously described [23], using reagents from R&D 
Systems DuoSet kits specific for the following human cytokines: IL-12 (DY1270), IL-10 
(DY217B), IL-8 (DY208), IL-6 (DY206) and TNF-a (DY210).   
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2.4 Cigarette smoke extract (CSE) preparation 
The procedure for generating CSE was based on that used in previous studies [24-31].  
Smoke generated from the combustion of a Marlboro Red cigarette (without filter, consistent 
with previous studies [24, 26-29], to ensure that all potential toxicants were present in the 
extract) was bubbled into phenol red-free RPMI medium (Sigma-Aldrich). The medium was 
then filtered through a 0.45µm filter and a dilution series of the CSE was prepared and 
absorbances measured using a Nanodrop ND-1000 spectrophotometer. The dilution required 
to obtain an absorbance of 0.15 was calculated; the resulting extract was designated 100% 
CSE.  A concentration range of 0.5%-3% CSE was used to treat moDCs, consistent with 
previous studies of the effects of CSE on cells in vitro [24, 27, 28, 30, 31].   
 
2.5 Treatment of moDCs with CSE or nicotine 
Day five immature moDCs were cultured for 24h with or without 100ng/ml LPS or 30µg/ml 
polyI:C in the absence, or presence, of 0.5% CSE, 3% CSE, 12µg/ml (-)-nicotine or 
200µg/ml (-)-nicotine (Sigma-Aldrich).  The chosen nicotine concentrations were based on 
12µg representing approximately 1% of the nicotine inhaled per cigarette (i.e. about 1.2mg 
per cigarette [32]) and 200µg representing approximately 1% of the nicotine inhaled by 
smoking 15-20 cigarettes per day [32]; these concentrations were also consistent with those 
used in previous studies [31, 33-35].  The treatments with CSE and nicotine had no 
significant effect on cell viability, as determined by flow cytometry (data not shown). 
 
2.6 Preparation of moDC lysates and RPPA processing 
The treated cells were harvested and washed in ice-cold PBS.  RIPA buffer (Thermo-
Scientific) supplemented with a 1:10 dilution of phosphate/protease inhibitor (Thermo-
Scientific) was added to the cells (1ml buffer per 5x106 cells).  The cells and buffer were 
mixed and the tubes were incubated on ice for 30min. The samples were then centrifuged at 
14,000g, 4°C for 15min.  The supernatants were stored at -80°C.  RPPA was performed 
essentially as described previously [21]; details are given in Supplementary table 2.  We 
previously validated the RPPA by showing strong correlation between results obtained by 
RPPA and conventional immunoblotting for detection of signaling molecules [21].  Samples 
that did not generate array features that conformed to stringent validation criteria (e.g. 
uniform shape and pixel density; signal to background ratio) were excluded from the 
analysis.  
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2.7 Statistical analysis 
Data for expression of CD markers and secreted cytokine concentrations were compared by 
Wilcoxon matched-pairs test.  The RPPA data passed the Kolmogorov-Smirnov test for 
normality and are presented with the means in scatter plots. Each individual reading is the 
mean of three replicates. One-way ANOVA was applied followed by Dunnett’s multiple 
comparison test; p£0.05 was considered significant. 
 
3. Results 
 
3.1 Effects of DC maturation on expression of CD markers, cytokines and signaling 
molecules 
Immature, monocyte-derived DCs (moDCs) were generated from PBMCs of healthy human 
donors and maturation was induced by treatment with 100ng/ml lipopolysaccharide (LPS) or 
30µg/ml poly I:C for 24h.  The effectiveness of LPS and polyI:C in inducing the maturation 
of moDCs is demonstrated in figure 1, which shows that these TLR agonists induced 
increased expression of CD-80, CD-86 and CD-83 (figure 1(i)), and secretion of IL-12, IL-
10, IL-8, IL-6 and TNF-a (figure 1(ii)). 
In addition, lysates of the immature, polyI:C and LPS treated moDCs were screened 
by RPPA for expression of 39 signaling molecules and other proteins associated with DC 
phenotype and functions.  The heat map of protein expression in the lysates (figure 1(iii)) 
shows that induction of DC maturation with LPS (centre columns) or poly I:C (right-hand 
columns) broadly upregulated expression of the protein molecules examined compared to 
their expression in immature DCs (left-hand columns).  
 
3.2 Effects of CSE and nicotine on moDCs 
Culturing immature moDCs with CSE (1% or 3%) or nicotine (12µg/ml or 200µg/ml) 
resulted in significant downregulation in expression of TNFL6, PIP5K1C, CXCR4, SOD1 
and MYD88, particularly by nicotine (Supplementary figure 1).  Culturing LPS-matured DCs 
with 200µg/ml nicotine also significantly suppressed expression of HGMB-1, Tollip and 
pNFkB-p65 (Supplementary figure 2).  The expression of other molecules examined was not 
significantly affected by CSE or nicotine in immature DCs or LPS-treated DCs (data not 
shown). 
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Culturing polyI:C-matured DCs with 3% CSE and both concentrations of nicotine 
suppressed expression of many of the proteins (Figure 2A; columns 3-5 compared to column 
1).  The quantitative analysis of this RPPA data is shown in figure 2B-E for the 17 proteins 
whose levels in the moDC lysates were significantly altered by the CSE and/or nicotine 
treatments during stimulation with polyI:C.  
Specifically, figure 2Bi-viii show proteins whose expression is associated with DC 
maturation and T cell stimulation (pNFkB-p65, c-REL, IRAK4, p-AKT Threonine, nNOS, 
HMGB1, TNFL6, IRAK-M): these showed lower expression in moDCs treated with CSE 
and/or nicotine.   Figure 2Ci-ii show proteins whose expression is associated with TLR-
dependent pathways of DC activation (MYD88, p-IRF3): these only showed higher 
expression with addition of 1% CSE.  Figure 2Di-ii show proteins whose expression is 
associated with cell survival (BCL-XL, SOD-1): these showed lower expression with 
addition of both CSE and nicotine.  Figure 2Ei-iii show proteins associated with migration 
(CXCR4, CD74, PIP5K1C): CXCR4 and PIP5KIC show lower expression with the addition 
of both CSE or nicotine, whereas CD74 shows higher expression with the addition of CSE or 
nicotine. 
 
4. Discussion 
 
This study demonstrates that CSE and nicotine inhibit the expression of proteins required for 
the activation, survival and migration of moDCs, as well as their ability to activate T cells.  In 
other words, constituents of tobacco smoke suppress the immunogenic potential of DCs.  
This provides a molecular basis for the reported inhibition of DC maturation and function by 
CSE and nicotine [6-19].  The concentrations of CSE (0.5% and 3%) and nicotine (12µg/ml 
and 200µg/ml) employed in this study were based on those used in previous studies [24, 27, 
28, 30, 31, 33-35]. Although the systemic blood concentrations of nicotine in smokers are 
much lower (20-60 ng/ml) [36, 37], our aim was to produce a reasonable model of the 
concentrations of cigarette smoke constituents (including nicotine) in the tissues of the 
respiratory tract directly exposed to these tobacco constituents during smoking.  In addition, 
nicotine is known to concentrate in particular body tissues, including the lung and spleen 
[36].   
The effects were most pronounced on poly I:C-stimulated DCs than on immature or 
LPS-stimulated moDCs.  This may be because, on the one hand, the expression levels of 
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signaling molecules in immature DCs are generally lower than in stimulated DCs, and so are 
less likely to be significantly suppressed by CSE or nicotine; on the other hand, LPS appears 
to up-regulate expression of the signaling molecules more strongly that does poly I:C, and so 
may be more resistant to suppression.  Furthermore, as discussed below, because poly I:C is a 
surrogate for the effects of viruses on DCs (whereas LPS is a bacterial product), this is 
especially relevant in the context of both viruses and smoking being recognized 
environmental factors in susceptibility to autoimmune diseases.  
Several proteins associated with DC maturation and T cell stimulation were 
downregulated by CSE and/or nicotine in poly I:C stimulated Dot. NF-kB subunits p65 and 
c-Rel were down-regulated – these promote T cell activation by DCs [38, 39]; IRAK-4 and 
AKT were down-regulated and contribute to DC maturation and T cell activation [40, 41].  
Neuronal nitric oxide synthase (nNOS) was downregulated by nicotine – this induces 
synthesis of nitric oxide in human DCs, necessary for their maturation [42].  HMGB1 was 
downregulated, which DCs secrete to promote activity and expansion of lymphocytes [43].  
TNFL6 (FasL/CD95L) is involved in activation-induced cell death, but also has co-
stimulatory properties [44].  IRAK-M inhibits DC activation and pro-inflammatory cytokine 
production [45]: its down-regulation in nicotine-treated DCs could be a feedback response to 
down-regulation of DC-stimulatory proteins. 
MYD88 and IRF-3 are involved in TLR-dependent DC activation [46, 47]:  their 
expression in polyI:C-stimulated DCs was not affected by nicotine or 3% CSE; however, 
both were significantly enhanced by 1% CSE.  This differential effect on human moDCs of 
low dose and higher dose CSE is consistent with the reported opposite effects of CSE on 
murine bmDCs dependent on length of exposure, with shorter exposure being stimulatory and 
longer exposure suppressive [12].   
Proteins associated with cell survival were also affected. BCL-XL, an anti-apoptotic 
factor required for DC survival [48], and SOD1 (superoxide dismutase-1), which promotes 
cell survival by removing reactive oxygen species [49], were donw-regulated in poly I:C-
stimulated moDCs by 3% CSE or nicotine, potentially leading to reduced DC viability. 
Expression of molecules associated with DC migration were affected in polyI:C-
stimulated DCs by 3% CSE, 12 and 200 µg/ml nicotine. CXCR4 promotes chemotaxis and 
survival of mature DCs [50] – this was down-regulated by 3% CSE or nicotine.  CD74, the 
MHC class II-associated invariant chain (Ii), was up-regulated by 3% CSE and nicotine.  
However, this may reduce DC migration since CD74 reduces DC motility [51].  PIP5K1C is 
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involved in cell migration [52] and its expression was reduced in moDCs by 3% CSE or 
nicotine.  Thus, CSE and nicotine inhibit the expression of proteins required for the 
activation, survival and migration of moDCs, and their ability to activate T cells. 
Cigarette smoking is a significant environmental risk factor for a variety of 
autoimmune diseases [53], including multiple sclerosis (MS) [54], systemic lupus 
erythematosus (SLE) [55] and rheumatoid arthritis [56].  In addition, cigarette smoke (CS) is 
the main environmental factor associated with chronic obstructive pulmonary disease 
(COPD), in which autoimmunity also plays a role [57-59].  The association of CS with both 
autoimmunity and immunosuppression is reminiscent of the well-documented association of 
autoimmunity with immunodeficiencies, in which it has been hypothesized that persistent 
infection, due to deficient immunity, can lead to the breakdown of tolerance and thus the 
generation of autoimmunity, which is of relevance here [60].  In this study, poly I:C mimics 
the action of the pathogen-associated molecular pattern (PAMP) viral double-stranded RNA.  
Virus infections are considered to be significant environmental factors in autoimmune 
diseases [61] and COPD [62], and the suppression of DC maturation by CS and nicotine 
could help to facilitate this. 
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Figure legends 
 
Figure 1.  i) Phenotypic analysis of moDCs by flow cytometry: the expression of the surface 
molecules was detected using a Beckman-Coulter FC500 flow cytometer. Anti-CD80-FITC, 
anti-CD86-PE, anti-CD83-PC5 and anti-DC-SIGN-PC7 conjugated antibodies were used for 
the extracellular staining of the cells and the data were analysed with Weasel v3.0.2. 
software. Comparison between the mean fluorescence intensity (MFI) values of immature 
and LPS- or poly I:C-treated (mature) moDCs presented as Box & Whisker plots showing the 
median, interquartile range and minimum and maximum values. Wilcoxon matched pairs test 
was used to assess statistical differences in marker expression between immature and mature 
DCs:   *p ≤ 0.05, ** p ≤ 0.01; n=8 for LPS-stimulated DCs and n=6 for poly I:C-stimulated 
DCs. ii) Comparison between cytokine secretion by immature and LPS- or polyI:C-treated 
(mature) moDCs (n=6).  The concentrations of IL-12, IL-10, IL-8, IL-6 and TNF-a secreted 
by immature, LPS- or polyI:C-matured DCs were determined using antibody microarray.  
Levels of IL-12 and IL-10 produced by immature DCs were undetectable.  Wilcoxon 
matched pairs test was used to assess differences in cytokine production between immature 
and mature DCs: in all cases p=0.03, except for stimulation of IL-8 production by polyI:C 
(p=0.06).  iii) Heat map of RPPA results for levels of 39 signaling molecules and other 
proteins in whole cell lysates of immature and mature human moDCs.  Each row shows 
expression of an individual protein in the lysates (indicated to the right).  Bright red indicates 
high protein expression; bright green indicates low protein expression. Each individual 
column represents the levels of the proteins in the lysates of moDCs generated from PBMC-
derived monocytes of different healthy donors (R1-R8).  The left-hand set of columns shows 
the results for immature DCs; the middle columns show the results for LPS-matured DCs; the 
right-hand columns show the results for polyI:C-matured DCs. 
 
 
 
Figure 2.  A) RPPA for polyI:C-matured human moDCs, with or without CSE or 
nicotine treatment.  Each row shows expression of an individual protein in the lysates 
(indicated to the right).  Bright red indicates high protein expression; bright green indicates 
low protein expression. Each individual column represents the levels of the proteins in the 
lysates of moDCs generated from PBMC-derived monocytes of different healthy donors (R1-
R8).  Each set of columns shows the results for DCs that were either untreated (1), or treated 
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with 1% CSE (2), 3% CSE (3), 12µg/ml nicotine (4) or 200µg/ml nicotine (5).  B-E) RPPA 
for poly I:C-treated human moDCs, with or without CSE or nicotine treatment. The analysis 
of 15 molecules is represented in scatter plots showing the means of each group. Each dot 
represents the mean of three replicates of the same normal individual. n=6 for controls and 
for 3% CSE-treated cells, n=7 for 1% CSE-treated cells, and n=8 for 12µg/ml and 200µg/ml 
nicotine-treated cells.  Figure 2Bi-viii show proteins whose expression is associated with DC 
maturation and T cell stimulation; figure 2Ci-ii show proteins whose expression is associated 
with TLR-dependent pathways of DC activation; figure 2Di-ii show proteins whose 
expression is associated with cell survival; figure 2Ei-iii show proteins associated with 
migration. 
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Supplementary table 1.  Primary antibodies used for the detection of cell surface differentiation markers by 
flow cytometry. 
 
 
Antibody 
specificity 
 
 
Clone 
 
Species 
 
Isotype 
 
Fluorescent label 
 
Source 
 
CD80 
 
 
IM1853U 
 
Mouse 
 
IgG1 
Fluorescein- 
isothiocyanate 
(FITC) 
 
Beckman-Coulter 
 
CD86 
 
 
IM2729U 
 
Mouse 
 
IgG2b 
 
Phycoerythrin 
(PE) 
 
Beckman-Coulter 
 
CD83 
 
 
IM3240U 
 
Mouse 
 
IgG2b 
Phycoerythrin- 
cyanin5 
(PE-Cy5) 
 
Beckman-Coulter 
 
CD209 
(DC-SIGN) 
 
 
25-2099-42 
 
Rat 
 
IgG2a 
 
Phycoerythrin- 
cyanin7 
(PE-Cy7) 
 
eBioscience 
 
Staining for flow cytometric analysis was performed as follows: samples were placed in PBA buffer 
(phosphate-buffered saline, 20% sodium azide, 30% bovine serum albumen, Sigma-Aldrich) and centrifuged 
at 300g for 5min. The supernatants were discarded and the pellets resuspended in 5µl of the appropriate 
monoclonal antibodies indicated in the table above; corresponding isotype control antibodies were also 
employed.  Incubation took place in the dark at room temperature for 30min and then 1ml PBA was added 
followed by centrifugation at 300g for 5min. Finally, the cells were fixed using 400µl of 0.5% formaldehyde 
and stored at 4°C prior to flow cytometry. 
  
 
Supplementary table 2.  Primary antibodies used in RPPA to detect proteins of interest in moDC lysates.  
All sourced from Cell Signaling Technologies, Schuttersveld 2, 2316 ZA Leiden, The Netherlands. 
Catalogue number (in brackets). 
 
Antibody 
specificity 
Species Dilutions 
 
Antibody 
specificity 
Species Dilution Antibody 
specificity 
Species Dilution 
c-REL 
(12707) 
Rabbit 1:200 Myd88 
(3699) 
Rabbit 1:50 pP38 
(4511) 
Rabbit 1:2000 
 
pMST1 
(3681) 
Rabbit 1:200 IRAK4 
(4363) 
Rabbit 1:200 pSTAT3 
(9145) 
Rabbit 1:50 
 
HMGB1 
(6893) 
Rabbit 1:200 P-IRAK4 
(7652-
discontinued) 
Rabbit 1:100 pHSP27 
(2401) 
Rabbit 1:50 
 
TNFSF6 
(5452) 
Rabbit 1:200 IRAK M 
(4369) 
Rabbit 1:50 pERK1/2 
(4370) 
Rabbit 1:250 
LSP-1 
(3812) 
Rabbit 1:100 IRAK2 
(4367) 
Rabbit 1:50 pAKT Threonine 
(9275) 
Rabbit 1:50 
 
nNOS 
(4231) 
Rabbit 1:100 Tollip 
(4748) 
Rabbit 1:100 pAKT Serine 
(9271) 
Rabbit 1:50 
 
PIP5K1C 
(3296) 
Rabbit 1:100 TAB2 
(3744) 
Rabbit 1:250 pCJun 
(9261) 
Rabbit 1:250 
CXCR4 
(97680) 
Rabbit 1:400 IRAK1 (Thr209) 
(4362-
discontinued) 
Rabbit 1:250 pNF-KB P65 
(3031) 
Rabbit 1:50 
CD74 
(77274) 
Rabbit 1:400 IRF3 
(4302) 
Rabbit 1:2000 
 
p STAT1 
(9177) 
Rabbit 1:250 
 
SOD1 
(4266) 
Mouse 1:400 P-IRF3 
(4947) 
Rabbit 1:2000 
 
p STAT4 
(4134) 
Rabbit 1:100 
 
 P-TAB2 
(8155) 
Rabbit 1:500 
 
P-ROS 
(3078) 
Rabbit 1:250 
 
NALPI 
(4990) 
Rabbit 1:500 
 
C FOS 
(2250) 
Rabbit 1:500 
 
P-IRF7 
(5184) 
Rabbit 1:500 
 
caspase8 
(4790) 
Rabbit 1:100 
 
 p BCL-2 
(2827) 
Rabbit 1:100 
 
BCL-XL 
(2764) 
Rabbit 1:250 
 
pSAPK/JNK 
(4668) 
Rabbit 1:500 
 
 
Cell lysates were solubilised in 4x SDS sample buffer at a 1:3 ratio and heated for 5min at 95°C.  Samples 
were loaded into a 384-well plates (Genetix). Samples were robotically spotted in duplicates as 16 separate 
arrays onto ONcyte Avid nitrocellulose-coated glass slides (GraceBiolab) using a microarrayer (MicroGrid 
II).  Slides were sealed in a 16-well Proplate incubation gasket (GraceBiolab) to isolate each replicated array 
and incubated overnight in blocking solution (0.2% I-block (Tropix), 0.1% Tween-20 in PBS) at 4°C with 
shaking. After washing, independent arrays on the slides were incubated with primary antibodies diluted in 
antibody diluent with background reducing agent (Agilent).  The antigenic specificity of all primary 
antibodies was verified by western blotting. Rabbit anti-b-actin antibody or mouse anti-b-actin (Sigma 
Aldrich), diluted 1:1000 in the same diluent, was used to monitor the abundance of housekeeping proteins to 
control for differences in protein loading. Slides were incubated overnight at 4°C with shaking.  Following 
washing, slides were incubated with diluted (1:5000 in washing buffer) secondary antibodies conjugated to 
infrared dyes, IRDYE-800CW goat anti-rabbit and IRDye-700CW goat anti-mouse (Li-Cor Biotechnology–
UK Ltd) for 30min at room temperature in the dark with shaking. Then, slides were washed and dried by 
centrifugation at 500g for 5min and scanned with a Li-Cor Odyssey SA scanner at 21µm resolution at 800 
nm (green) and 700 nm (red). The resultant TIFF images were processed with Axon Genepix Pro-6 
Microarray Image Analysis software (Molecular Devices) to obtain fluorescence data for each feature and to 
generate standard gpr files. Protein signals were finally determined after background subtraction and 
normalization to the internal housekeeping targets using the RPPanalyzer, a module within the R statistical 
language on the CRAN (http://cran.r-project.org/). 
 
 
Supplementary figure 1.  RPPA for immature human moDCs, with or without CSE or nicotine treatment.  
Each row shows expression of an individual protein in the lysates (indicated to the right).  Bright red 
indicates high protein expression; bright green indicates low protein expression. Each individual column 
represents the levels of the proteins in the lysates of moDCs generated from PBMC-derived monocytes of 
different healthy donors (R1-R8).  Each set of columns shows the results for DCs that were either untreated 
(1), or treated with 1% CSE (2), 3% CSE (3), 12µg/ml nicotine (4) or 200µg/ml nicotine (5).  The analysis 
of 5 molecules is represented in scatter plots (i – v) showing the means of each group. Each dot represents 
the mean of three replicates of the same normal individual. n=7 for all controls, 1% CSE, and 12µg/ml and 
200µg/ml nicotine treatment, and n=6 for 3% CSE-treated cells. 
 
 
Supplementary figure 2.  RPPA for LPS-matured human moDCs, with or without CSE or nicotine 
treatment.  Each row shows expression of an individual protein in the lysates (indicated to the right).  Bright 
red indicates high protein expression; bright green indicates low protein expression. Each individual column 
represents the levels of the proteins in the lysates of moDCs generated from PBMC-derived monocytes of 
different healthy donors (R1-R8).  Each set of columns shows the results for DCs that were either untreated 
(1), or treated with 1% CSE (2), 3% CSE (3), 12µg/ml nicotine (4) or 200µg/ml nicotine (5).  The analysis 
of 3 molecules is represented in scatter plots (i – iii) showing the means of each group. Each dot represents 
the mean of three replicates of the same normal individual. n=6 for controls, 1% CSE- and 3% CSE-treated 
cells; n=7 for 12 µg/ml nicotine-treated cells and n=8 for 200 µg/ml nicotine-treated cells. 
 
